Day: January 7, 2026

STRM.BIO Raises $8 Million in Series Seed 2 Financing to Advance Non-Viral Gene Delivery Platform for In Vivo Cell Engineering and Gene Therapy

Recordati Joins Boehringer Ingelheim Venture Fund in Financing Round, with Participation from Delos and Blue Bay CapitalNew Investment, Combined with...

STRM.BIO Raises $8 Million in Series Seed 2 Financing to Advance Non-Viral Gene Delivery Platform for In Vivo Cell Engineering and Gene Therapy

Recordati Joins Boehringer Ingelheim Venture Fund in Financing Round, with Participation from Delos and Blue Bay CapitalNew Investment, Combined with...

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by leveraging generative chemistry design...

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by leveraging generative chemistry design...

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Partnership addresses the unmet need for remyelination therapies for multiple sclerosis and other demyelinating conditions by leveraging generative chemistry design...

error: Content is protected !!